Research associate (CR1), INSERM 1039, Bioclinical Radiopharmceuticals Laboratory (LRB), Grenoble-Alpes University (UGA), France (since 2014)
- Post-doctoral fellow, INSERM 1039, Bioclinical Radiopharmceuticals Laboratory (LRB), Grenoble-Alpes University (UGA), France (2008-2014)
- Post-doctoral fellow, Experimental Nuclear Cardiology, University of Virginia, VA, USA (2005-2008)
- DHDR (research management certificate), Grenoble-Alpes University, 2013
- PhD in Biomedical Engeneering, Grenoble-Alpes University, 2005
The main goal of the Bioclinical Radiopharmaceuticals Laboratory (LRB), INSERM 1039, is to develop new radiopharmaceuticals dedicated to nuclear imaging. To fulfil this objective, the LRB developed several skills, from the selection of the target to be imaged to the clinical trial. As a Research Associate in this laboratory, I am in charge to develop radiopharmaceuticals dedicated to the non-invasive imaging of cardiovascular inflammation. A radiotracer targeting at the Vascular Cell Adhesion molecule 1 (VCAM-1) adhesion protein has been fully characterized. This new imaging agent, that allowed non invasive imaging of atherosclerosis lesions in mice, is currently under clinical translation.